Metronidazole is a small uncharged molecule that exerts its biologic activity through reduction of its nitro group.
STRUCTURE AND DERIVATION
Metronidazole is a nitroimidazole derivative. Its chemical name is 2-methyl-5-nitroimidazole-1-ethanol. Metronidazole vaginal gel 0.75% is administered as a single 5-g dose via intravaginal applicator. Each gram of MetroGel-Vaginal contains 7.5 mg of metronidazole in a gelled, purified water solution, containing 0.8 mg of methylparaben, 0.2 mg of propylparaben, propylene glycol, carbomer 934p, sodium hydroxide (to adjust pH), and edetate disodium. The gel is formulated at pH 4.0 (normal vaginal pH) and is free of mineral oil. Each applicatorful delivers 5 g of gel, containing approximately 37.5 mg of metronidazole.
MECHANISM OF ACTION
Metronidazole is a small uncharged molecule that exerts its biologic activity through reduction of its nitro group. 3 Anaerobic or microaerophilic conditions promote activation of metronidazole. 4 The action of metronidazole is believed to consist of three successive steps: s entry of the drug into target cells, activation by a reduction process, and toxic effects of the reduced product. The reduction of the nitro group of the 5-nitroimidazole results in the formation of toxic derivatives, which kill susceptible bacteria by interacting with DNA. 4, 5 The reduction of metronidazole in anaerobic organisms most likely occurs in a one-electron step and is assumed to lead first to the formation of a free radical anion. 4, 5 The proposed site of metronidazole reduction is the pyruvate phosphoroclastic reaction in which feredoxin serves as the terminal electron acceptor. 4 ,s This process, and thus the level of antimicrobial activity, is markedly influenced by the oxygen tension of the environment. 4 
PHARMACOKINETICS
The bioavailability of metronidazole varies according to the route of administration. 6 Intravenous or oral administration of metronidazole results in nearly 100% bioavailability, and the drug diffuses readily to nearly all body tissues. 7 Topical administration (rectal or intravaginal) reduces the bioavailability, resulting in lower serum concentrations of the drug. 7, 8 Metronidazole is metabolized by the liver into acid and hydroxy metabolites. In a randomized, single-blind controlled trial of metronidazole vaginal gel 0.75% vs. oral metronidazole, the incidence and severity of gastrointestinal adverse events reported by subjects who received the intravaginal gel was lower than those reported by subjects who received oral metronidazole (P 0.014). This is likely due to the minimal systemic exposure metronidazole vaginal gel 0.75% produces relative to oral metronidazole. The product is contraindicated in patients with a prior history of hypersensitivity to metronidazole, parabens, or other ingredients of the formulation. Oral metronidazole has been reported to potentiate the anticoagulant effect of warfarin and other coumarin anticoagulants, resulting in a prolongation of prothrombin time. 13 This possible drug interaction should be considered when metronidazole vaginal gel 0.75% is prescribed for patients on this type of anticoagulant therapy.
SPECTRUM OF ANTIMICROBIAL ACTIVITY
Metronidazole is a widely used antimicrobial agent that is active against both anaerobic bacteria and protozoa. 14 
